Chad Lewis

About Chad Lewis

Dr. Chad Lewis oversees the production of all K36 pharmaceutical agents. He brings over 20 years of chemistry experience across academic, pharmaceutical, and biotech environments.Prior to joining K36, Dr. Lewis was the Associate Director of Chemistry at FogPharma where he managed the chemistry group for stapled peptide synthesis and development. Chad also served as a Senior Principal Scientist at Pfizer and led a multidisciplinary team for the multi-ton process chemistry development of the JAK1 inhibitor, Abrocitinib, for the treatment of atopic dermatitis. Prior to Pfizer, he was an Assistant Professor of Chemistry at Cornell University where he researched the synthesis of rare marine toxin alkaloids and carbasugar synthetic methods. Dr. Lewis earned his B.Sc. in Chemistry with Honors at the University of Alberta, a Ph.D. in Chemistry at Yale University, and was a Postdoctoral Fellow at The Scripps Research Institute. He has authored a book chapter, several patents, and co-authored more than 20 academic publications ranging from new synthetic methods to organocatalysis.

Experience

1. Executive Director of Technical Operations

   K36 Therapeutics, Inc

   Mar 2025 — Present

Education

• Boston College

  Chemistry

  2003 — 2006

• The Scripps Research Institute

  Postdoctoral Scholar, Total synthesis of marine natural products

  2008 — 2010

• Marist College School of Management

  Masters in Business Administration, Financial Management

• University of Alberta

  Bachelor of Science - Chemistry with Honors, Chemistry

  1997 — 2002

• Yale University

  Doctor of Philosophy (Ph.D.), Chemistry

  2005 — 2008

Skills

• Spectroscopy
• Chemistry
• Organometallic Chemistry
• Catalysis
• Organic Synthesis
• Hplc
• Organic Chemistry
• Nmr
• Mass Spectrometry
• Biochemistry